Comparison of Enamel Preparations - Bevel, Chamfer and Stair Step Chamfer on Fracture Resistance of Nano Filled Resin Composites Using Bulk Pack Technique - An In Vitro Study

AIM: To evaluate and compare the effect of enamel preparation designs bevel, chamfer and stair-step chamfer on the fracture resistance of nanocomposite. METHODS: The sample group of this study consisted of 72 non-carious permanent maxillary central incisors. The sample is divided into four groups of 18 each. Group, I control Group II bevel preparation, Group III chamfer preparation, group IV stair step chamfer preparation. After the specific preparation, each tooth is filled with nanocomposite using bulk pack technique. The teeth were subjected to fracture resistance test under Universal testing machine and then were examined under a stereomicroscope to evaluate the type of bond failure. The results were subjected to statistical analysis. RESULTS: Results of the One-Way ANOVA revealed a significant difference in the mean peak failure load values of the four different groups. (P < 0.001) Tukey’s Post-Hoc comparison test revealed that there was a significant difference in the mean peak failure load values of the bevel and chamfer preparation. But there was no significant difference between chamfer and stair-step chamfer preparation designs. CONCLUSION: Stair-step chamfer preparation demonstrated comparable values to Chamfer preparation but also involved the removal of less amount of tooth structure adjacent to the fractured edge and good esthetic technique

Pattern of diabetic foot - presentation and complications in rural Indian population

Background: Foot ulcer is one of the most common and deadest complications of diabetes mellitus. This is also a frequent cause of hospitalization and disability. Most of the patients with diabetic foot ulcers living in developing countries present to healthcare facilities fairly late with advanced foot ulcers because of poor economic status, inadequate knowledge of self-care, sociocultural reasons and poor and inadequate diabetes healthcare.Methods: A prospective study was conducted in the department of Surgery, JNMC Sawangi (Meghe), Wardha of DMIMS (DU) with the aim to evaluate the pattern of distribution of foot ulcers in diabetic foot patients and related complications. We enrolled 30 diabetic patients in the study, of these 21 (70%) were males and 9 (30%) were females with male to female ratio 2.33.  Results: The mean age of presentation was 52.93 ± 14.10 and the mean duration of diabetes was 8.20 ± 10.06. The maximum numbers of lesion was present in the region of second to fifth metatarsal (53.33%), followed by heel (26.66%) and great toe (10%). Maximum patients 9 (30%) had grade II lesions as per Wagner’s classification and 12 (40%) had II B as per University of Texas diabetic wound classification. Associated deformity was present in 36.66%, insensitivity to the 5.07 S-W monofilaments in 56.66%, impaired vibration in 43.33%, and abnor­mal Achilles tendon reflex in 40%. Ankle–brachial index <0.8 was present in 33.33%. Only 13.33% patients were using customized footwear whereas 46.66% were walking barefoot, the difference was statistically significant P = 0.0027.Conclusion: The health education to promote Knowledge, Attitude, Behavior and Practice (KABP) is essential to prevent diabetes associated foot complications.

Pigeonpea nutrition and its improvement

Pigeonpea (Cajanus cajan [L.] Millsp.), known by several vernacular and names such as red gram, tuar, Angola pea. yellow dhal and oil dhal, is one of the major grain legume crops of the tropics and sub-tropics. It is a crop of small holder dryland fmmers because it can grow well under subsistence level of agriculture and provides nutritive food, fodder, and fuel wood. It also improves soil by fixing atmospheric nitrogen. India by far is the largest pigeonpea producer it is consumed as decorticated split peas, popularly called as 'dhaL' In other countries, its consumption as whole dty and green vegetable is popular. Its foliage is used as fodder and milling by-products [onn an excellent feed for domestic animals. Pigeonpea seeds contain about 20-22% protein and appreciable amounts of essential amino.acids and minerals. DehuHing and boiling treatments of seeds get rid of the most antinutritional factors as tannins and enzyme inhibitors. Seed storage causes considerable losses in the quality of this legume. The seed protein of pigeonpea has been successfully enhanced by breeding from 20-22% to 28-30%. Such lines also agronomically performed well and have acceptable and color. The high-protein lines were found nutritionally superior to the cultivars because they would provide more quantities of utilizable protein and sulfur-containing amino acids

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Cultural Influences on Corporate Social Responsibility

To date, research that demonstrates what Corporate Social Responsibility (CSR) actually means in terms of policies and practices in the pharmaceutical industries is scarce. Similarly, research that shows understanding or compares the cultural influences of the East and the West on CSR in the pharmaceutical industry is also scarce

Epidural clonidine for postoperative pain after lower abdominal surgery: A dose - response study

Background: Patient controlled epidural analgesia with local anesthetic and opioid is an effective technique for postoperative analgesia after abdominal surgery. Clonidine has a synergistic effect on epidural local anesthetics. The purpose of this study was to determine the optimal epidural clonidine dose to be added to a solution of bupivacaine and morphine for patient controlled epidural analgesia to deliver an optimal balance of analgesia and side effects. Methods: Sixty patients were randomly assigned to three study groups (C0, C1, C2) of 20 patients each. Before the induction of general anesthesia, epidural anesthesia was induced using 10 mL of 1% lidocaine and epinephrine (1:200,000) and was maintained with a continuous infusion of the lidocaine - epinephrine solution until the completion of surgery. After surgery, groups CO, C1, and C2 received patient controlled epidural analgesia (PCEA) with morphine (0.1 mg/mL) in 0.1% bupivacaine. Group C1 and C2 also received epidural clonidine (1 and 2 mcg/mL, respectively). Pain was assessed at rest, cough, and on movement at 1, 2, 4, 8, 12 h after surgery and on day 1, 2, and 3. Differences in the mean postoperative Numerical Rating Scale (NRS) score and analgesic consumption were assessed by one-way analysis of variance and multiple comparisons. Result: Patients in all the groups experienced adequate pain relief during the 72-h period after surgery. There was no statistically significant difference between the mean NRS scores and CRS scores for pain at rest, cough, or during mobilization between the three groups. The cumulative volumes of analgesic solution were C0, 131 ± 21.285 mL; C1, 89.9 ± 18.44 mL; and C2, 80.1 ± 21.32 mL. There was no significant difference in the PCEA analgesic consumption between group C1 and C2 (P = 0.128). Groups C1 and C2 required lower volume of analgesic solution (P < 0.001) than group C0. Also, the number of rescue doses consumed by clonidine group were less (P < 0.001). Conclusion: The optimal epidural clonidine concentration in a morphine (0.1 mg/mL) and bupivacaine (0.1%) solution after lower abdominal surgery is 1.0 μg/ml. The combination of bupivacaine (0.1 %), morphine (0.1%), and clonidine (both 1 and 2 μg/mL) resulted in excellent pain relief in the 72 hour period after surgery and was not accompanied by significant hypotension, sedation, sensory blockade, or motor blockade